CD274 and non-small cell lung carcinoma: Monotherapy with pembrolizumab is the standard of first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) and a programmed Death ligand-1 (PD-L1) tumor proportion score (TPS) ≥ 50%.